Research information only, not medical advice. Gonadorelin is a synthetic decapeptide identical to natural gonadotropin-releasing hormone (GnRH), which stimulates the pituitary to release LH and FSH. Its branded US products — Factrel (diagnostic use) and Lutrepulse (pulsatile pump therapy) — were FDA-approved but were voluntarily withdrawn from the market for commercial reasons, not safety or efficacy. As of 2026 no FDA-approved gonadorelin product is commercially available in the US; it is used off-label, mainly via compounding pharmacies, including as a testicular-function adjunct during testosterone therapy — an off-label use with no large randomised controlled trials.
Gonadorelin at a glance
Gonadorelin's historical evidence base comes from the diagnostic and pulsatile-therapy trials that supported its former FDA approvals (Factrel for pituitary-gonadotroph function testing, Lutrepulse for pulsatile treatment of hypothalamic amenorrhoea). Those products were withdrawn from the US market in commercial decisions, not for safety reasons. Its current off-label use — preserving testicular function during testosterone replacement therapy — has not been evaluated in large randomised controlled trials; the evidence for that specific use is limited.
See how we grade evidence for the methodology behind this page.
Evidence profile
353 studies- Human trial 18 · 5%
- Review 108 · 31%
- Animal 137 · 39%
- In-vitro 42 · 12%
- Unknown 48 · 14%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
Clinical trials
-
Psychostimulant Abuse - Novel Treatment Approaches - 1
-
The Effects of Reproductive Hormones on Mood and Behavior
-
The Role of Hormones in Postpartum Mood Disorders
-
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
-
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
-
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
-
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
-
Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome
-
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
-
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
-
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum
-
Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
-
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
-
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
-
Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer
-
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
-
Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism
-
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
-
Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study
-
Clinical Trial for Prostate Cancer
-
Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer
-
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
-
Dose-Response of Gonadal Steroids and Bone Turnover in Older Men
-
Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids
-
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
-
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
-
Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer
-
Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy
-
S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer
-
Lupron Sex Offender Therapy
-
Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone
-
Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer
-
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
-
Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
-
CMAB vs IMAB in Metastatic Prostate Cancer
-
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
-
FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer
-
Casodex/Zoladex Biomarkers in Localised Prostate Cancer
-
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH
-
Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients
-
Prostate Adenocarcinoma TransCutaneous Hormones
-
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
-
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
-
Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
-
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
-
Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer
-
Investigation of Early Hormonotherapy Efficacy of Prostate Cancer
-
Pulsatile GnRH in Anovulatory Infertility
-
Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)
-
Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF Drugs
-
Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
-
Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation
-
Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer
-
Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer
-
Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
-
Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy
-
Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
-
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
-
The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study
-
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
- NCT00456144 COMPLETED
Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer
-
Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)
-
A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer
-
Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism
-
GnRH Agonist and Antagonists in an Oocyte Donation Program
-
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
-
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
-
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
-
Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty
-
Gonadotropin-releasing Hormone Antagonist on Triggering Day: A Randomized Controlled Study
-
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
-
Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy
-
Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer
-
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
-
Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism
-
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
-
Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer
-
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
-
Study of Lupron Depot In The Treatment of Central Precocious Puberty
-
Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer
-
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
-
Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles
-
Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy
-
Prevention of Obesity in Women Via Estradiol Regulation
- NCT00702234 COMPLETED
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)
- NCT00702520 COMPLETED
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)
- NCT00702546 COMPLETED
Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)
- NCT00702624 COMPLETED
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)
-
PGL4001 Versus GnRH-agonist in Uterine Myomas
-
Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids
-
Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
-
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
-
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
-
Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)
-
Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c
-
Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients
-
A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height
-
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
-
A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF)
-
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
-
Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study
-
Kisspeptin Administration in the Adult
-
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
-
Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer
-
Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment
-
Outcome of Two Protocols in Poor Responders in Assisted Reproductive Technology (ART) Cycle
-
Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles
-
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
-
Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles
-
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
- NCT01081873 COMPLETED
Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer
-
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
-
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
-
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
-
Neoadjuvant Ipilimumab in Prostate Cancer
-
Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy
-
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
-
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
-
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
-
Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls
- NCT01311037 UNKNOWN
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer
-
Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing In Vitro Fertilisation
-
Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer
-
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
-
Preservation of Ovarian Function After Hematopoietic Cell Transplant
-
Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide
-
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
-
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
-
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
-
Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
-
A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)
-
An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females
-
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
-
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
-
A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs
-
FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer
-
Efficacy and Safety of TAK-385 in the Treatment of Endometriosis
-
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
-
Endometrial Receptivity After GnRH Agonist Triggering
- NCT01510054 WITHDRAWN
Endometrial Luteal Phase Characteristics and Luteal Phase Support in Controlled Ovarian Stimulation Protocols With GnRH Antagonists:Focusing on MicroRNA
-
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
-
Relationship Between the Menstrual Cycle and Heart Disease in Women
-
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
-
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
-
Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression
-
The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis
-
Gonadotropin-releasing Hormone Agonist Prior to Myomectomy
-
Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity
-
Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation
-
A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis
-
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
-
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
-
The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol
-
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
-
Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation
-
Study of Red Bull™ Sugar-Free Drink for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH Agonist Therapy
-
The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.
-
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
-
Degarelix in the Treatment of Endometriosis Recurrence
-
Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer
-
Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol
-
Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin
-
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
-
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
-
Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
-
Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients
-
Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence
-
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
-
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery
-
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
- NCT01793077 COMPLETED
Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients
-
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
- NCT01813097 COMPLETED
Combination Iodine 125 Seed Implants and LHRH Agonists for Locally Advanced (Stage T3) Prostate Cancer
-
Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
-
Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer
-
Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel
-
Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women
-
Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders
-
A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease
- NCT01942369 COMPLETED
A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months
-
LH Response to GnRH Test in Prepubescent Girls Under 6 Years
-
Evaluation of Granulosa Cells Function After IVF Protocols
-
The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization.
-
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
-
Neuropeptides in Human Reproduction
-
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
-
Efficacy Study Evaluating Chemotherapy in Prostate Cancer
-
The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes
-
TRial on the Endocrine Activity of Neoadjuvant Degarelix
-
Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome
-
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
-
Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures
-
A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT
-
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
-
AMH Levels Change During Treatment With GnRh Agonist
- NCT02091557 COMPLETED
CA 125 and VAS Pain Score Changes to Diagnose Endometriosis
-
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
-
The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes
-
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
-
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
- NCT02134977 COMPLETED
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"
-
GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian Response
-
Bay98-7196, Dose Finding / POC Study
-
Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2
- NCT02234089 COMPLETED
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
- NCT02238366 COMPLETED
Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer
-
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
-
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
-
Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy
-
Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration
-
Comparative Study Between Minidose Long Protocol and Microdose Flare Protocol in Controlled Ovarian Hyperstimulation
-
Detect V / CHEVENDO (Chemo vs. Endo)
-
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
-
Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas
- NCT02366494 COMPLETED
Micro RNAs to Predict Response to Androgen Deprivation Therapy
- NCT02381821 COMPLETED
Endometrial Volume and Sub-endometrial Vascularity as Predictors of In-vitro Fertilization Success
-
A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants
-
Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
-
Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases
-
Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
-
Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer
-
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
-
Corifollitropin Alfa on D5 Versus D7 After Contraceptive Pill
-
Biosimilar Versus Urinary Gonadotropins
-
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
-
Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity
-
GnRHa Combined With hCG and hMG for Treatment of Patients With Non-obstructive Azoospermia
-
MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population
-
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
-
Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT)
- NCT02595255 RECRUITING
AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)
-
Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer
- NCT02607293 COMPLETED
A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation
-
GnRH Agonist as Luteal Support in FET Cycles
-
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
- NCT02630641 COMPLETED
Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.
-
Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol
-
Reprometabolic Syndrome Mediates Subfertility in Obesity
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
- NCT02673632 UNKNOWN
The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS
-
Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients
-
Effects of Sex Steroids on the Serotonin System
-
Efficacy and Safety of Medication Used to Stimulate Ovulation
-
A Study of Definitive Therapy to Treat Prostate Cancer
-
Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
-
Cardiovascular Outcomes of Low Testosterone
-
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
-
AASUR in High Risk Prostate Cancer
-
Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome
-
Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
-
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
-
Random-start Ovarian Stimulation in Egg-donors (ROSE)
-
Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study
-
Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer
-
Combination of Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin Triggered by Normal Responder in GnRH-antagonist Cycles
-
Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels
-
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation
-
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
-
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
-
Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer
-
Triggering of Follicular Maturation
-
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer
-
Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control
-
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
-
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
-
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
-
Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate
-
Effects of SNP of GnRH Receptor Genes in IVF Patients
-
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
-
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
-
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
-
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
-
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
-
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
-
Menopausal Sleep Fragmentation and Body Fat Gain
-
Systemic Hormones and Muscle Protein Synthesis
-
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
-
Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET
-
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
-
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
-
Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI
-
A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）
-
Hormonal Mechanisms of Sleep Restriction - Axis Study
-
The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies
- NCT03209518 COMPLETED
Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
- NCT03230994 UNKNOWN
Cooperative Adenomyosis Network
-
Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
-
Menopause Effects on Vascular Function
-
Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol
-
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
-
Agonist Versus Classical HCG Trigger (Poor Responders, Normoresponders and High Responders)
-
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
-
Early Preparation With Gonadotropin- Releasing Hormon (GnRh) Agonists Injection With Frozen-Thawed Embryo Transfer?
-
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
-
Prostate Boost Irradiation With Stereotactic Body RT (SBRT)
-
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
-
The Influence of Gonadal Hormone Suppression on Adipocyte Lineage and the Microbiome
-
Neoadjuvant Endocrine Therapy in Breast Cancer
-
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
-
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
-
Neoadjuvant Goserelin for Triple Negative Breast Cancer
-
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant
-
IVM Versus Standard IVF in Infertile Patients Diagnosed With PCOS
-
Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide
-
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
-
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
- NCT03516110 COMPLETED
Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy
-
Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males
-
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
- NCT03543059 UNKNOWN
A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer Patients
-
HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer
-
PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases
-
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
-
Follicle Size and Oocyte Development
-
Comparison of a Novel Leuprolide With Market Leuprolide
-
Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)
-
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
-
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
-
Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF
-
Accuracy of Ultrasound Markers Versus Biochemical Markers in Prediction of Ovarian Response in Obese Women Undergoing IVF/ICSI Treatment
- NCT03703778 ACTIVE_NOT_RECRUITING
Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)
-
Surgery and ART For Endometrioma
-
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)
-
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)
-
Follicular Fluid Sialic Acid Levels in IVF Cycles
-
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
-
The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation
-
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
-
EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control.
- NCT03867357 COMPLETED
Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia
-
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
-
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate
-
Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis
-
Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis
-
Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI in Adenomyosis
-
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
-
FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer
-
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
-
A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
- NCT03990194 WITHDRAWN
Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer
-
Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS
-
Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study
-
INTREPId (INTermediate Risk Erection PreservatIon Trial)
- NCT04037488 UNKNOWN
Changes in Body Composition With Patients Under Androgen Deprivation Therapy
-
Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
-
Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist at Different Periods of the Menstrual Cycle
-
GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET
-
Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
-
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
-
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy
-
The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer
-
Cohort Study Investigating the Association Between Antichlamydial Antibody Positivity and ART Outcomes in Women With TFI
-
Cardiovascular Events in GnRH Agonist vs. Antagonist
- NCT04188275 UNKNOWN
CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION
-
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
-
PREOPERATIVE GONADOTROPINE-RELEASING HORMONE AGONIST THERAPY BEFORE SURGERY FOR UTERİN FIBROIDS
-
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
-
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
-
GnRH Therapy on Cognition in Down Syndrome
- NCT04400942 UNKNOWN
Predictive Factors for Complete Myoma Resection During Hysteroscopic Myomectomy
-
Corifollitropin Alpha and Ovarian Response
-
Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis
-
The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol
-
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
-
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
-
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
-
Controlled Ovarian Stimulation Versus Modified Natural Cycles in Poor Responders
-
Role of Suppression of Endometriosis With Progestins Before IVF-ET
-
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
-
RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2
-
Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
-
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
-
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
-
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
-
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
-
Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts
-
Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients
-
Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
-
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI
-
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI
-
Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate
-
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
-
Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin
-
The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer
-
Agonist Trigger With HCG Luteal Supplementation vs HCG Trigger With Progesterone Luteal Supplementation in Antagonist Controlled HyperstimulationCycle
- NCT04854707 COMPLETED
An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data
-
Intramuscular Injection of Human Chorionic Gonadotropin in Frozen Embryo Transfer Cycles
-
Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant
-
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
-
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
-
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
-
An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
-
SRT Versus SRT+ADT in Prostate Cancer
-
Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)
-
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
-
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
-
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
- NCT05087706 UNKNOWN
Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）
- NCT05122377 COMPLETED
RWE About QOL and Compliance of Patients With OFS in China
-
Luteal Phase Support With Daily Administration of Gonadotropin-releasing Hormone Agonist Compared to Progesterone/Estradiol in IVF/ICSI Cycles With Ovulation Triggering With GnRH-a
-
Roll-over Study to Allow Continued Access to Ribociclib
-
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
-
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
-
Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
-
A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation
-
Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support
-
Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.
-
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
-
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A
- NCT05341128 COMPLETED
A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China
-
COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES
-
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
-
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
-
Luteal Phase Ovarian Stimulation With Follitropin Delta and Dydrogesterone
- NCT05567198 RECRUITING
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
-
A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer
-
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
-
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
-
Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment
-
A Multicenter Open-label Clinical Study on the Prevention of Premature Ovarian Failure After HSCT
-
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
- NCT05677269 RECRUITING
The (Cost-)Effectiveness of Surgical Excision of Colorectal Endometriosis Compared to ART Treatment Trajectory
-
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
-
Contributions to Hypertension With Androgen Deprivation Therapy
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
-
Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy
-
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
-
Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles
- NCT05778331 UNKNOWN
The Difference Between POSEIDON Group 3 and Group 4 as Regards IVF
-
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
-
DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT
-
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
-
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
-
Kisspeptin Administration Subcutaneously to Patients With IHH
-
To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone
-
Recall by Genotype: Neuropeptide Stimulation
-
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
-
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
-
Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF
-
Evaluate the Efficacy and Safety of DWJ108J
-
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
-
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
-
GnRH-a on Angiogenesis of Endometriosis
-
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
-
Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery
- NCT06145958 NOT_YET_RECRUITING
Radiotherapy and Androgen Deprivation In Combination After Local Surgery (RADICALS) Translational Study
-
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
-
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
-
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
- NCT06217770 COMPLETED
Retrospective Study to Assess Real-Life Use of The Long Acting GnRH Agonist as Prostate Cancer Treatment
-
Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients
-
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
-
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
-
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
-
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
-
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
-
Adaptions and Resiliency to Multi-Stressor OpeRations
-
An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation
-
Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility
-
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
-
An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.
-
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
-
Effect of a GnRH Analog on Hepatic Steatosis
-
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
-
Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer
-
Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)
-
Combination of TURP and Standard Systemic Therapy for MPCa
-
Study on Human Bioequivalence of Triprerelin Acetate for Injection
- NCT06812559 COMPLETED
Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome
-
Sexual Coercion in Breast Cancer Patients Treated With Luteinizing Hormone-Releasing Hormone Agonists (LHRHa )
-
Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.
-
The COSMYC Trial (COmbined Suppression of MYC)
-
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
- NCT07076719 COMPLETED
Cell-free DNA Analysis of Spent Embryo Culture Media as a Non-invasive Approach for Preimplantation Genetic Diagnosis
-
A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants
-
Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy
-
Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment
-
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
-
A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer
-
COMPASS - COpenhagen MenoPAuSe Study
-
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
-
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
-
Comparison of IVF Outcomes Between PPOS and Antagonist Protocols in Women With PCOS
-
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
-
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
-
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
-
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
-
Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study
- NCT07519213 COMPLETED
Guangdong Endometriosis Retrospective Clinical Cohort
-
Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders
-
RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
-
PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
-
Effect of GnRH Agonist in FET
-
Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis
-
A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty
-
Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis
Indexed research
Sorted by evidence level, strongest first.
- Human trial 2026Restoring ovulation in functional hypothalamic amenorrhea: impact of polycystic ovarian morphology on hormonal response to pulsatile GnRH
This observational study found that women with functional hypothalamic amenorrhea and polycystic ovarian morphology had higher baseline AMH levels and no significant AMH increase after pulsatile GnRH therapy, unlike those without PCOM.
- Human trial 2026Protocol flexibility in PCOS: a combination of controlled ovarian stimulation and endometrial preparation strategies shows no impact on live birth outcomes after frozen embryo transfer-a retrospective cohort study
This retrospective cohort study found that in PCOS patients, live birth rates after frozen embryo transfer did not significantly differ among various combinations of controlled ovarian stimulation protocols and endometrial preparation methods.
- Human trial 2026Diagnostic performance of a simplified GnRH stimulation test in central precocious puberty: a multicentre study
This multicentre study evaluated whether shortening the GnRH stimulation test by measuring luteinizing hormone at 60 minutes maintains diagnostic accuracy for central precocious puberty in children.
- Human trial 2025Diagnostic accuracy of the triptorelin stimulation test for central precocious puberty in girls
This retrospective study evaluated the diagnostic accuracy of subcutaneous triptorelin compared to intravenous gonadorelin for diagnosing central precocious puberty in girls, finding comparable accuracy with an optimal LH peak cut-off of 7.14 IU/L at 180 minutes.
- Human trial 2025Is the triptorelin stimulation test comparable to the gonadorelin stimulation test in diagnosing central precocious puberty in boys?
This letter compares the diagnostic accuracy of triptorelin stimulation test versus gonadorelin stimulation test for central precocious puberty in boys.
- Human trial 2026Diagnostic Usefulness of Subcutaneous Triptorelin Stimulation Testing in the Evaluation of Central Precocious Puberty in Girls
This retrospective study of 662 girls with suspected central precocious puberty found that subcutaneous triptorelin stimulation testing yields similar luteinizing hormone response patterns to gonadorelin and may be a practical diagnostic alternative.
- Human trial 2026Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
This multicenter cohort study found that extended endocrine therapy was associated with lower risks of invasive and distant recurrence across all surrogate breast cancer subtypes in premenopausal patients with node-positive, hormone receptor-positive early breast cancer, with the greatest risk reduction observed in luminal A-like disease.
- Human trial 2026Dynamic Profiles of Serum Kisspeptin and DLK1 During GnRH Stimulation in Central Precocious Puberty and Premature Thelarche
This cross-sectional study found that dynamic changes in serum kisspeptin and DLK1 during GnRH stimulation differ between girls with central precocious puberty and premature thelarche, but diagnostic utility is limited due to considerable overlap.
- Human trial 2026Supplementary Material for: Dynamic Profiles of Serum Kisspeptin and DLK1 During GnRH Stimulation in Central Precocious Puberty and Premature Thelarche
This cross-sectional study examined dynamic serum kisspeptin and DLK1 levels during GnRH stimulation in girls with central precocious puberty and premature thelarche, finding distinct percentage changes at 60 minutes that may help differentiate the conditions but with uncertain diagnostic utility.
- Human trial 2026Supplementary Material for: Dynamic Profiles of Serum Kisspeptin and DLK1 During GnRH Stimulation in Central Precocious Puberty and Premature Thelarche
This study found that the dynamic responses of serum kisspeptin and DLK1 to GnRH stimulation differ between girls with central precocious puberty and premature thelarche, though their diagnostic utility remains uncertain.
+ 343 more studies indexed for Gonadorelin.
Frequently asked questions
- Is Gonadorelin approved for human use?
- Gonadorelin is a synthetic decapeptide identical to natural gonadotropin-releasing hormone (GnRH), which stimulates the pituitary to release LH and FSH. Its branded US products — Factrel (diagnostic use) and Lutrepulse (pulsatile pump therapy) — were FDA-approved but were voluntarily withdrawn from the market for commercial reasons, not safety or efficacy. As of 2026 no FDA-approved gonadorelin product is commercially available in the US; it is used off-label, mainly via compounding pharmacies, including as a testicular-function adjunct during testosterone therapy — an off-label use with no large randomised controlled trials.
- What does the research on Gonadorelin show?
- Gonadorelin's historical evidence base comes from the diagnostic and pulsatile-therapy trials that supported its former FDA approvals (Factrel for pituitary-gonadotroph function testing, Lutrepulse for pulsatile treatment of hypothalamic amenorrhoea). Those products were withdrawn from the US market in commercial decisions, not for safety reasons. Its current off-label use — preserving testicular function during testosterone replacement therapy — has not been evaluated in large randomised controlled trials; the evidence for that specific use is limited.